Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minh Ngoc Duong

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal for Immunotherapy of Cancer|November 7, 2019
Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytesMinh Ngoc Duong, Efe Erdes, Michael Hebeisen, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 29, 2013
Bone marrow stem cellsMinh Ngoc Duong, Yu-Ting Ma, Ray C J Chiu
Oncotarget|September 17, 2017
The fat and the bad: Mature adipocytes, key actors in tumor progression and resistanceMinh Ngoc Duong, Aline Geneste, Frederique Fallone, et al.
Mabs|December 20, 2014
Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodiesMinh Ngoc Duong, Eva-Laure Matera, Doriane Mathé, et al.
Breast Cancer Research : BCR|April 25, 2015
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicityMinh Ngoc Duong, Aurore Cleret, Eva-Laure Matera, et al.
Frontiers in Immunology|December 1, 2017
Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated MechanismsDanilo Presotto, Efe Erdes, Minh Ngoc Duong, et al.
JCI Insight|July 21, 2017
TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potencyMathilde Allard, Barbara Couturaud, Laura Carretero-Iglesia, et al.
Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal for Immunotherapy of Cancer|November 7, 2019
Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytesMinh Ngoc Duong, Efe Erdes, Michael Hebeisen, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 29, 2013
Bone marrow stem cellsMinh Ngoc Duong, Yu-Ting Ma, Ray C J Chiu
Oncotarget|September 17, 2017
The fat and the bad: Mature adipocytes, key actors in tumor progression and resistanceMinh Ngoc Duong, Aline Geneste, Frederique Fallone, et al.
Mabs|December 20, 2014
Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodiesMinh Ngoc Duong, Eva-Laure Matera, Doriane Mathé, et al.
Breast Cancer Research : BCR|April 25, 2015
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicityMinh Ngoc Duong, Aurore Cleret, Eva-Laure Matera, et al.
Frontiers in Immunology|December 1, 2017
Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated MechanismsDanilo Presotto, Efe Erdes, Minh Ngoc Duong, et al.
JCI Insight|July 21, 2017
TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potencyMathilde Allard, Barbara Couturaud, Laura Carretero-Iglesia, et al.
Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.
Pageof 1